Scinus Cell Expansion
Scinus Cell Expansion, a Dutch biotech founded in 2016, develops the Osilaris automated benchtop bioreactor platform — a closed, GMP-compliant system with proprietary Carboxygenator oxygenation — for scalable cell therapy manufacturing. It serves ATMP manufacturers, CDMOs, academic hospitals, and pharma companies, primarily across Europe.
- Company typePrivate
- Founded2016
- HeadquartersBilthoven, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Scinus Cell Expansion does
Scinus Cell Expansion Netherlands B.V. is a Dutch private biotechnology company founded in 2016 and headquartered at Utrecht Science Park in Zeist. The company designs and sells the Osilaris automated benchtop bioreactor platform — a closed, GMP-compliant, Class C cleanroom-ready system that enables high-fold (>1000x) expansion of adherent or suspension cells in a single, volume-expandable passage. The platform's two proprietary technical anchors are the patented Carboxygenator oxygenation system (bubble-free, shear-free gas exchange with continuous pH and dissolved-oxygen feedback control) and a volume-expandable single-use culture bag that scales to the equivalent of more than 200 T175 flasks. The platform supports protocols for MSCs, T-cells, HEK293T, iPSCs, organoids, viral vectors, and extracellular vesicles, and has been integrated with Buoyancy-Activated Cell Sorting (BACS) for in-bioreactor T-cell selection. Scinus has been on market for approximately two years and is installed at several European academic ATMP manufacturers and multiple ATMP CDMOs.
The company operates a B2B enterprise sales model targeting four primary segments: academic and commercial ATMP manufacturers, ATMP CDMOs, academic hospitals/research centers, and pharma/biotech companies. Revenue is generated through three streams: sale of the Osilaris bioreactor as capital equipment, recurring revenue from single-use consumables (culture bags in adherent and suspension variants, perfusion loops, gas-permeable tubing), and process development services for customer-specific cell types and protocols. Pricing is quotation-based with multi-year contracts; an e-commerce storefront exists for consumable reorders. Scinus employs approximately 20 people and is backed by founders (Prof. Dr. Joost de Bruijn, Prof. Dr. Clemens van Blitterswijk, Frank-Jan van der Velden), Demcon (strategic investor and industrial engineering partner since 2019), and Myosotis Investments, which led a €3 million strategic round in March 2026 alongside a CEO transition to Dr. Erik Vossenaar. The company participates in at least eight EU-funded research consortiums (NXTGEN Hightech, RHYTHMS, TENTACLE, LIBRA, InnoCAR-T, FIT, Excellent, BEACON) and holds ISO 9001 certification, with the Prix Galien MedTech Innovation Award (2022) as its most prominent independent recognition.
Scinus Cell Expansion firmographics
Firmographics- Name
- Scinus Cell Expansion
- Legal name
- Scinus Cell Expansion Netherlands B.V.
- Website
- https://scinus.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Scinus Cell Expansion, a Dutch biotech founded in 2016, develops the Osilaris automated benchtop bioreactor platform — a closed, GMP-compliant system with proprietary Carboxygenator oxygenation — for scalable cell therapy manufacturing. It serves ATMP manufacturers, CDMOs, academic hospitals, and pharma companies, primarily across Europe.
- Ownership category
- akta.pro rank
Scinus Cell Expansion industry classification
Industry- Product category
- Cell Therapy Manufacturing Equipment
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industries
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Scinus Cell Expansion is headquartered
LocationHeadquarters
- HQ city
- Bilthoven
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Scinus Cell Expansion business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Osilaris Bioreactor System (Capital Equipment): Sale of the Osilaris automated bioreactor platform as capital equipment to ATMP manufacturers, academic hospitals, CDMOs, and pharma companies for GMP-compliant cell therapy manufacturing.
- Osilaris Consumables: Sale of single-use consumables including adherent and suspension culture bags with integrated sensors, perfusion loops, and specialized gas-permeable tubing for the Osilaris platform. Recurring revenue through replenishment orders.
- Process Development Services: Custom protocol development and process optimization services for various cell types (MSC, T-cell, iPSC, HEK293T, organoids) on the Osilaris platform, supporting customer-specific manufacturing needs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom quotation-based pricing for equipment and consumables |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
Scinus Cell Expansion product offering
Product offeringCore offering
Scinus Cell Expansion develops and sells the Osilaris™, an automated benchtop bioreactor platform for GMP-compliant cell therapy manufacturing. The system enables high-fold (>1000x) expansion of adherent or suspension cells from a single cryovial to clinical dose in a single passage, supported by single-use consumable culture bags and process development services. Target customers are ATMP manufacturers, CDMOs, academic hospitals, and pharma/biotech companies engaged in cell and gene therapy production.
Product overview
Scinus Cell Expansion offers the Osilaris™ platform as its core product offering for scalable cell therapy manufacturing. The platform consists of the Osilaris™ automated bioreactor (the main instrument), Osilaris™ Consumables (single-use culture bags and accessories), and Process Development services. The Carboxygenator is a key patented component of the system that provides bubble-free oxygenation through gas-permeable tubing. The system supports both adherent and suspension cell culture, enabling >1000x cell expansion from a single cryovial to clinical doses in a single passage, with GMP-compliant and closed-system design for decentralized cell therapy manufacturing.
Differentiator
Problem solved
Functional benefit
Brands
- Osilaris™: Automated scalable bioreactor platform for cell therapy manufacturing, designed for high-fold expansion of adherent or suspension cells with proven protocols for MSC, T-cells, HEK, iPSC manufacturing.
- Carboxygenator
Products and services
- Osilaris™ Bioreactor Automated benchtop bioreactor system for GMP-compliant cell therapy manufacturing, designed for high-fold (>1000x) expansion of adherent or suspension cells in a single passage. Features a closed, Class C cleanroom-ready design with integrated pH and dissolved oxygen sensors, perfusion-based media exchange, and the proprietary Carboxygenator oxygenation system. Targets ATMP manufacturers, CDMOs, academic hospitals, and pharma/biotech companies.
- Osilaris™ Consumables Single-use culture bags (adherent and suspension variants), perfusion loops, and gas-permeable tubing components designed for use with the Osilaris bioreactor. The volume-expandable bag can dynamically grow with the cell population, accommodating the surface area equivalent of more than 200 traditional T175 culture flasks. Generates recurring revenue through replenishment orders from existing Osilaris customers.
- Process Development Services Custom protocol development and process optimization services for various cell types (MSC, T-cell, iPSC, HEK293T, organoids) on the Osilaris platform. Supports customer-specific manufacturing needs, helps establish protocols for new cell types, and enables transition from R&D to clinical-grade production. Sells to ATMP manufacturers, CDMOs, and academic hospitals.
Quantifiable outcome
- High-fold expansion >1000x in a single passage from vial to clinical dose
- +4 more outcomes
Companies that use Scinus Cell Expansion
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Scinus Cell Expansion technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Scinus Cell Expansion partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core, major, significant, technology enhancement, regional, academic, commercial, integration, clinical, customer, ecosystem and scientific advisory.
- Demcon (Industrial Group)coreDemcon group (1,100+ employees, locations in Best, Delft, Enschede, Groningen, Leiden, Maastricht, Scheveningen, Münster Germany, Tokyo Japan, Singapore, and USA) partnered with Scinus in 2019 to industrialize the cell expansion technology into a robust platform for cellular biotherapy manufacturing. Michiel Jannink, former CEO and now Strategic Advisor, served as VP Life Science & Health at Demcon while leading Scinus.
- NXTGEN Hightech (Biomedical Cell Production Technologies)majorConsortium program (13 partners) developing next-generation cell production technologies with automation and consistent yields at the core. Scinus focuses on testing and integrating technologies into its bioreactor systems, including new sensor technology from Eindhoven University of Technology and animal component-free culture media.
- RHYTHMS Consortium (Eurostars)significantEurostars-funded collaboration between Scinus, MyCellHub, Stemmatters, and Skåne University Hospital aiming to decentralize cell manufacturing with high-quality cells. Develops sensor modules, decentralized software solutions for real-time culture monitoring, and robust expansion protocols for sensitive cell types like iPSC.
- TENTACLE ConsortiumsignificantEU-funded project developing an innovative colonoscopic bioprinter for colorectal disease treatment. Scinus develops processes to provide sufficient patient-specific cells from small biopsies for use in the bioprinter's bio-ink, combining cells with biomaterials for intestinal wall reconstruction.
- LIBRA Project Consortiumtechnology enhancementEU Horizon-funded project developing a compact multi-sensing device for automated screening of bioreactor cultivation processes. Integrates photonic platforms with disposable microfluidic modules and biofunctionalization units for nutrient and pathogen contamination monitoring. Scinus contributes bioreactor and cell cultivation expertise and validates the LIBRA prototype.
- InnoCAR-T (Marie Curie European Doctorate)significantHorizon Europe Marie Curie training network for innovative CAR-T concepts incorporating bioreactor technology, gene editing, and nanotech-based drug delivery. Scinus contributes lentiviral particle production using the Osilaris bioreactor, process development for gene-edited CAR-T manufacturing at Point of Care facilities, and nanoparticle strategy implementation.
- MIT R&D ENGAGE CAR-NKsignificantMIT R&D project combining Scinus bioreactor technology with Glycostem's expertise in CAR-NK cell generation. Develops new processes for efficient engineering and expansion of CAR-NK cells to advance off-the-shelf CAR-NK products toward clinical stage.
- FIT Interreg Meuse-Rhein ConsortiumregionalInterreg project (co-funded by EU) involving universities of Maastricht, Leuven, Liège, Hasselt, Aachen, and SMEs including Scinus, to valorize optimized muscle stem cell technology for muscle disease treatment. Five technology-driven work-packages for production and administration innovation.
- Excellent Project ConsortiumregionalSNN-funded project (Just Transition Fund) building an expertise hub for cell therapy technology in the North-East of the Netherlands. Scinus contributes automation knowledge and development for CAR-T and TIL therapy applications, partnering with University Hospital Groningen and Demcon.
- BEACON Collaboration (Erasmus MC)academicCollaboration with Dr. Monique Verstegen's group at Erasmus University Medical Center Rotterdam (under Erasmus MC-TKI-LSH Match call) for liver graft repair. Uses Osilaris to expand cholangiocyte organoids during machine perfusion to repair damaged bile ducts of extended criteria donor livers.
- RoosterBiocommercialCollaboration on automating hMSC-EV (extracellular vesicle) manufacturing in the Osilaris bioreactor. Scinus provides the bioreactor platform while RoosterBio contributes hMSCs and media. Joint application note published.
- Thermo Fisher ScientificintegrationCollaboration on MSC harvest with downstream processing using Osilaris and Rotea counterflow centrifugation system. Application note published covering expansion and downstream processing of adherent cells.
- Aarhus University Hospital (Center for Gene and Cellular Therapy)clinicalDanish center established in 2022 with funding from the Danish Innovation Fund. Incorporating Osilaris into GMP stem cell therapy workflow for clinical studies and patient treatment, aiming to obtain Danish Medicines Agency approval for Osilaris-produced cells.
- Skåne University Hospital (ATMP-Center)clinicalPartnership for advances in cell and gene therapy. Milestone celebrated in presence of Dutch Minister for Foreign Trade Reinette Klever and VNO-NCW Chair Ingrid Thijssen.
- KU Leuven (Prometheus Division)academicLong-standing academic collaboration. Prof. Liesbet Geris and team use Osilaris as gold standard for MSC and periosteum-derived cell expansion, with Scinus representing the gold standard technology for patient-specific expansion of cells for large bone defects.
- ReGEN BiomedicalcustomerCustomer using Osilaris as key investment toward future manufacturing goals. System addresses next-generation requirements including closed setup, integrated sensors, low shear stress, bubble-free gas exchange, and integrated seed train.
- Smart BioMaterials Center (SBMC)ecosystemSBMC brought together medtech and biomaterials experts including Scinus for The Great Small Talk Show series, exploring how convergence of medtech and biomaterials shapes future therapy development.
- Frank P. Luyten (Prometheus/KU Leuven/RegmedXB)scientific advisoryScientific Advisory Board member. Professor Emeritus at KU Leuven and Medical/Scientific Director of RegmedXB. Principal inventor of more than 15 granted patents/patent families, co-founder of TiGenix (later acquired by Takeda).
- Willem E. Fibbe (LUMC)scientific advisoryScientific Advisory Board member. Emeritus professor of Hematology and Stem Cell Biology at Leiden University Medical Centre, former member of EMA's Committee for Advanced Therapies (CAT), co-founder of Starfish Innovations.
Scale indicators4 records
Recent moves7 records
Expansion highlights7 records
Scinus Cell Expansion competitors and assessment
Company assessmentDirect peers
- Miltenyi Biotec: Miltenyi's Prodigy platform is the most direct competitor to Osilaris, offering automated, closed-system cell processing and expansion for CAR-T, T-cell, and other cell therapy manufacturing in a GMP-compliant benchtop footprint.
- Cytiva (formerly GE Healthcare Life Sciences): Cytiva's Xuri Cell Expansion System is a rocking-bed bioreactor widely adopted for cell therapy manufacturing, including CAR-T and MSC production at CDMOs and academic centers competing with Scinus for similar accounts.
- Sartorius: Sartorius offers the Biostat and ambr bioreactor families used across cell and gene therapy development and manufacturing, competing head-to-head with Osilaris at ATMP manufacturers and CDMOs globally.
- Lonza: Lonza's Cocoon platform is a closed, automated cell therapy manufacturing system that competes with Osilaris in autologous and allogeneic cell therapy production at CDMOs and large pharma customers.
- Terumo BCT: Terumo BCT's Quantum Cell Expansion System is a hollow-fiber bioreactor used for cell therapy manufacturing (including MSC and iPSC workflows), directly competing with Osilaris at academic and commercial cell therapy customers.
Emerging players
- PBS Biotech: PBS Biotech provides single-use, vertical-wheel bioreactors used in cell and gene therapy applications, overlapping with Scinus's suspension cell culture use cases for T-cell, MSC, and viral vector production.
- RoosterBio: RoosterBio supplies hMSC and media kits and has a documented collaboration with Scinus on automating hMSC-EV manufacturing in the Osilaris bioreactor, making it a complementary technology partner and partial competitor in MSC-derived workflow content.
Broad incumbents
- Eppendorf: Eppendorf's BioFlo and DASbox bioreactor lines serve cell culture and cell therapy process development and manufacturing, representing a broader-incumbent alternative to Scinus in research and clinical cell expansion.
- Corning Life Sciences: Corning provides a wide portfolio of cell culture vessels (CellSTACK, HYPERStack) and single-use technologies used in cell therapy manufacturing; while not a benchtop bioreactor specialist, its scale-up vessels compete for the same upstream expansion workflow as Osilaris.
- Thermo Fisher Scientific (Cell Therapy): Thermo Fisher offers Gibco cell culture media, CTS products, and the Rotea counterflow centrifugation system (integrated downstream to Osilaris via a published application note), serving as both an ecosystem partner and broad incumbent across the cell therapy manufacturing workflow.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Scinus Cell Expansion social profiles
Digital presenceScinus Cell Expansion compliance and trust
Trust signalCompliance2 records
Scinus Cell Expansion financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scinus Cell Expansion leadership team
Management profileNumber of profiles
Profiles17 records
Scinus Cell Expansion funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scinus Cell Expansion M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scinus Cell Expansion
What does Scinus Cell Expansion do?
Scinus Cell Expansion develops and sells the Osilaris™, an automated benchtop bioreactor platform for GMP-compliant cell therapy manufacturing. The system enables high-fold (>1000x) expansion of adherent or suspension cells from a single cryovial to clinical dose in a single passage, supported by single-use consumable culture bags and process development services. Target customers are ATMP manufacturers, CDMOs, academic hospitals, and pharma/biotech companies engaged in cell and gene therapy production.
Is Scinus Cell Expansion a public or private company?
Scinus Cell Expansion is a private company. It is classified as venture growth investor backed and is currently operating.
When was Scinus Cell Expansion founded?
Scinus Cell Expansion was founded in 2016. It employs 1 to 10 people.
Where is Scinus Cell Expansion based?
Scinus Cell Expansion is headquartered in Bilthoven, Netherlands, in the Europe region.
How does Scinus Cell Expansion make money?
Three revenue lines are on record. Osilaris Bioreactor System (Capital Equipment) is the primary driver. The others are osilaris Consumables and process Development Services.
Who are Scinus Cell Expansion's main competitors?
Direct peers on record are Miltenyi Biotec, Cytiva (formerly GE Healthcare Life Sciences), Sartorius, Lonza and Terumo BCT. Emerging players are PBS Biotech and RoosterBio. Broad incumbents are Eppendorf, Corning Life Sciences and Thermo Fisher Scientific (Cell Therapy).
Does Scinus Cell Expansion have an API?
No public API is recorded for Scinus Cell Expansion.
What industry is Scinus Cell Expansion in?
Scinus Cell Expansion's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 334510 and its SIC code is 3845.